Reviewers from the FDA, the American drug agency equivalent to Anvisa in Brazil, reported this Sunday night (12/6), that the Pfizer vaccine against Covid-19 is effective and safe for children between 6 months and 4 years old.
When reviewing data from the US drugmaker’s studies, the team found no safety concerns related to vaccinating young children.
Copy of 3 Cards_Gallery_of_Photos (1)
After approval by the National Health Surveillance Agency (Anvisa) and authorization by the Ministry of Health, the pediatric dose of the Covid-19 vaccine is already being administered in Brazil to children between 5 and 11 years old. However, parents should be careful to avoid errors in the application of the immunizing agent in small children. Pixabay
According to Fiocruz, vaccinating children against Covid is necessary to prevent the circulation of the virus at high levels, in addition to ensuring the health of the little ones.Pixabay
Although a medical prescription is not required for vaccination, the federal government recommends that parents consult a health professional before taking their children for the vaccine.Brazil Agency
According to Anvisa, the vast majority of post-vaccination adverse events are due to the administration of the wrong product to the age group, the inadequate dose and the wrong preparation of the product.Brazil Agency
The children’s vaccine comes in an orange packaging, unlike the version for over 12 years old, which is purple. The syringe used is 1ml, and the volume applied must be 0.2mlBrazil Agency
The correct identification of doses for children aged 5 to 11 years is an obligation of public authorities, which must also ensure efficient training for all responsible staff.Brazil Agency
According to Pfizer, the amount applied to children was carefully selected based on safety and immunogenicity data.Brazil Agency
The pharmaceutical’s clinical studies indicated a lower possibility of adverse reactions in the use of lower doses. Immune responses were also more efficient because children typically have a more robust immune response. Rafaela Felicciano / Metropolis
According to Pfizer data, about 7% of children who received a dose of the vaccine had some reaction, but in only 3.5% the events were related to the immunizing agent. none of them were seriousRafaela Felicciano / Metropolis
The immunizer proved to be 80.3% effective in preventing the disease among children in this age group in a study sample of 10 symptomatic cases of Covid-19 when the Omicron variant of the coronavirus was dominant.
The FDA’s external consultants will meet this Wednesday (15/6) to hit the hammer on the recommendation to use the immunizer.
With information from Reuters Agency
Get news from metropolises on your Telegram and stay on top of everything! Just access the channel: https://t.me/metropolesurgente.